Floatz logo

WARFARIN

Hemorrhage

McMaster UniversitySmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Hemorrhage cohort.

Asset / SponsorPhaseRating
Tranexamic Acid
Daniel Nishijima, MD, MAS
Phase 4BBB
PROPRANOLOL
Shanghai Zhongshan Hospital
Phase 4BB
Acetylsalicylic Acid
Chonnam National University Hospital
Phase 4BB
CHLORHEXIDINE
Beijing Tiantan Hospital
Phase 4BB
Plavix
Chonnam National University Hospital
Phase 4BB

View all 20 →

Same molecule, other indications

WARFARIN is also rated in:

venous thromboembolismDormant
A
Indicative ·
81 / 100
View asset →
atrial fibrillationDormant
BBB
Indicative ·
77 / 100
View asset →
hemorrhagic diseaseDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →